Erytech Pharma SA (NASDAQ:ERYP) – Investment analysts at Jefferies Financial Group increased their FY2019 earnings estimates for shares of Erytech Pharma in a research note issued to investors on Tuesday, March 12th. Jefferies Financial Group analyst P. Welford now anticipates that the company will post earnings per share of ($3.62) for the year, up from their previous forecast of ($3.76). Jefferies Financial Group also issued estimates for Erytech Pharma’s FY2020 earnings at ($3.50) EPS, FY2021 earnings at ($3.50) EPS and FY2022 earnings at ($3.62) EPS.
ERYP has been the subject of a number of other research reports. Zacks Investment Research raised shares of Erytech Pharma from a “hold” rating to a “buy” rating and set a $8.50 target price for the company in a report on Monday, November 19th. ValuEngine lowered shares of Erytech Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd.
A hedge fund recently bought a new stake in Erytech Pharma stock. Sphera Funds Management LTD. bought a new position in shares of Erytech Pharma SA (NASDAQ:ERYP) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 120,000 shares of the company’s stock, valued at approximately $1,046,000. Sphera Funds Management LTD. owned approximately 0.67% of Erytech Pharma as of its most recent SEC filing. Institutional investors own 8.16% of the company’s stock.
About Erytech Pharma
ERYTECH Pharma SA, a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia.
Further Reading: Why is the price-sales ratio important?
Receive News & Ratings for Erytech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erytech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.